It is a light-emitting device that can be implanted near a tumour through a small incision, by needle-injection, or during surgery and powered wirelessly by a radio-frequency field. The light delivered by the device activates light-sensitive drugs (photodynamic therapy), destroying malignant cells with minimal side effects outside of the treatment region.
It is a miniaturized (30 mg, 15 mm3) implantable photonic device and wireless powering system with the following key advances:
1. deep operation near organs at human size scales
2. multiwavelength light emission at radiant power levels optimized for photosensitizer activation
3. wireless control of light emission for therapeutic dosimetry.
It enables illumination of volumes up to 130 mm3 (assuming a hemisphere volume of radius 4 mm), which is about 8 times the volume of the device.
Tested for hepatocellular carcinoma and gliobastoma
Potentially also for: other cancers, wet-aged related macular degeneration, psoriasis and atherosclerosis.
Primary market: Oncology market
Specific market: Photodynamic therapy market